Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells

Acta Biochimica et Biophysica Sinica

Volumn 45, Issue 9, 2013, Pages 773-779

  Hua, Hanju ^a   Chen, Wenbin ^a   Shen, Ling ^b   Sheng, Qinsong ^a   Teng, Lisong ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Apoptosis; Colorectal cancer; Honokiol; Nuclear factor B; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; CASPASE 3; CYCLOOXYGENASE 2; HERBACEOUS AGENT; HONOKIOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGNAN; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PLATINUM COMPLEX; PROSTAGLANDIN E2; PROTEIN KINASE B; VASCULOTROPIN A;

APOPTOSIS; ARTICLE; CELL LINE; CELL PROLIFERATION; CELL STRAIN HT29; CELL SURVIVAL; COLON TUMOR; COLORECTAL CANCER; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; METABOLISM; NUCLEAR FACTOR-ΚB; PATHOLOGY; WESTERN BLOTTING;

APOPTOSIS; COLORECTAL CANCER; HONOKIOL; NUCLEAR FACTOR-ΚB; OXALIPLATIN;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CASPASE 3; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUGS, CHINESE HERBAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HT29 CELLS; HUMANS; LIGNANS; NF-KAPPA B; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS C-AKT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84883218955     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt071     Document Type: Article

References (33)

1. Kweekel DM, Gelderblom H and Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treatment Rev 2005, 31: 90-105.
2. Cavalettia G, Tredicib G and Petrucciolic MG. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001, 37: 2457-2463.
3. Pasetto LM, D'Andrea MR and Rossi E. Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol 2006, 59: 159-168.
4. Han LL, Xie LP, Li LH and Zhang XW. Reactive oxygen species production and Bax/Bcl-2 regulation in honokiol-induced apoptosis in human hepatocellular carcinoma SMMC-7721 cells. Environ Toxicol Pharmacol 2009, 28: 97-103.
5. Hibasami H, Achiwa Y, Katsuzaki H, Imai K, Yoshioka K, Nakanishi K and Ishii Y, et al. Honokiol induces apoptosis in human lymphoid leukemia Molt 4B cells. Int J Mol Med 1998, 2: 671-673.
6. Battle TE, Arbiser J and Frank DA. The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood 2005, 106: 690-697.
7. Liu H, Zang C, Emde A and Maricarmen D. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. Eur J Pharmacol 2008, 591: 43-51.
8. Park EJ, Min HY and Chung HJ. Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells. Cancer Lett 2009, 277: 133-140.
9. Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Hideshima H and Shiraishi N, et al. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood 2005, 106: 1794-1800.
10. Hahm ER and Singh SV. Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity. Mol Cancer Ther 2007, 6: 2686-2695.
11. Yang SE, Hsieh MT, Tsai TH and Hsu SL. Down-modulation of Bcl-XL, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells. Biochem Pharmacol 2002, 63: 1641-1651.
12. Lin JW, Chen JT, Hong CY, Lin YL, Wang KT, Yao CJ and Lai GM, et al. Honokiol traverses the blood-brain barrier and induces apoptosis of neuroblastoma cells via an intrinsic bax-mitochondrion-cytochrome c-caspase protease pathway. J Neuro Oncol 2012, 14: 302-314.
13. Steinmann P, Walters DK, Arlt MJ, Banke IJ, Ziegler U, Langsam B and Arbiser J, et al. Antimetastatic activity of honokiol in osteosarcoma. Cancer 2012, 18: 2117-2127.
14. Spencer AG, Woods JW, Arakawa T, Singer II and Smith WL. Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy. J Biol Chem 1998, 273: 9886-9893.
15. Smith WL, Marnett LJ and DeWit DL. Prostaglandin and thromboxane biosynthesis. Pharmacol Ther 1991, 49: 153-179.
16. Pugh S and Thomas GA. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 1994, 35: 675-678.
17. Sheng H, Shao J, Washington MK and DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001, 276: 18075-18081.
18. Nithipatikom K, Isbell MA, Lindholm PF, Kajdacsy-Balla A, Kaul S and Campell WB. Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. Clin Exp Metastasis 2002, 19: 593-601.
19. Casibang M, Purdom S, Jakowlew S, Neckers L, Zia F, Ben Av P and Hla T, et al. Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. Lung Cancer 2001, 31: 203-212.
20. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002, 2: 795-803.
21. Takekoshi K, Isobe K, Yashiro T, Hara H, Ishii K, Kawakami Y and Nakai T, et al. Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas. Life Sci 2004, 74: 863-871.
22. Iovino F, Ferraraccio F, Orditura M, Antoniol G, Morgillo F, Cascone T and Diadema MR, et al. Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer. Cancer Invest 2008, 26: 250-255.
23. Mora A, Komander D, Van Aalten DM and Alessi DR. PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol 2004, 15: 161-170.
24. Yoeli-Lerner M and Toker A. Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle 2006, 5: 603-605.
25. Brazil DP, Yang ZZ and Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004, 29: 233-242.
26. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and González-Barón M. PI3 K/Akt signalling pathway and cancer. Cancer Treat Rev 2004, 30: 193-204.
27. Martelli AM, Tabellini G, Bortul R, Tazzari PL, Cappellini A, Billi AM and Cocco L. Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias. Histol Histopathol 2005, 20: 239-252.
28. Martelli AM, Faenza I, Billi AM, Manzoli L, Evangelisti C, Fala F and Cocco L. Intranuclear 30-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? Cell Signal 2006, 18: 1101-1107.
29. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE and Navolanic PM, et al. Roles of the RAF/MEK/ERK and PI3 K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Reg 2006, 46: 249-279.
30. Park IS, Jo JR and Hong H. Aspirin induces apoptosis in YD-8 human oral squamous carcinoma cells through activation of caspases, down-regulation of Mcl-1, and inactivation of ERK-1/2 and AKT. Toxicol In Vitro 2010, 24: 713-720.
31. Troppmair J, Bruder JT, Munoz H, Lloyd PA, Kyriakis J, Banerjee P and Avruch J, et al. Mitogen-activated protein kinase/extracellular signal regulated protein kinase activation by oncogenes, serum, and 12-O tetradecanoylphorbol- 13-acetate requires Raf and is necessary for transformation. J Biol Chem 1994, 269: 7030-7035.
32. Nakayama H, Ikebe T, Beppu M and Shirasuna K. High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 2001, 92: 3037-3044.
33. Kallergi G, Agelaki S, Kalykaki A, Stournaras C, Mavroudis D and Georgoulias V. Phosphorylated EGFR and PI3 K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res 2008, 10: R80.